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Abstract: 
Background: Evidence on the efficacy of palliative care in persons with 
severe multiple sclerosis (MS) is scarce.  
Objective: To assess the efficacy of a home-based palliative approach 
(HPA) for adults with severe MS and their carers.  
Methods: Adults with severe MS-carer dyads were assigned (2:1 ratio) to 
either HPA or usual care (UC). At each center, a multi-professional team 
delivered the six-month intervention. A blind examiner assessed dyads at 
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baseline, three and six months. Primary outcome measures were Palliative 
care Outcome Scale-Symptoms-MS (POS-S-MS), and Schedule for the 
Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW, not 
assessed in severely cognitively compromised patients).  
Results: Of 78 dyads randomized, 76 (50 HPA, 26 UC) were analyzed. 
Symptom burden (POS-S-MS) significantly reduced in HPA group compared 
to UC (p=0.047). Effect size was 0.20 at three, 0.32 at six months, and 
statistical significance borderline in per-protocol analysis (p=0.062). 
Changes in SEIQoL-DW index did not differ in the two groups, as changes 
in secondary patient and carer outcomes.  
Conclusions: HPA slightly reduced symptoms burden. We found no 
evidence of HPA efficacy on patient quality of life, and on secondary 
outcomes.  
Trial registration number: ISRCTN73082124. 
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ABSTRACT 
Background: Evidence on the efficacy of palliative care in persons with severe multiple 
sclerosis (MS) is scarce. 
Objective: To assess the efficacy of a home-based palliative approach (HPA) for adults 
with severe MS and their carers. 
Methods: Adults with severe MS-carer dyads were assigned (2:1 ratio) to either HPA or 
usual care (UC). At each center, a multi-professional team delivered the six-month 
intervention. A blind examiner assessed dyads at baseline, three and six months. 
Primary outcome measures were Palliative care Outcome Scale-Symptoms-MS (POS-S-
MS), and Schedule for the Evaluation of Individual Quality of Life-Direct Weighting 
(SEIQoL-DW, not assessed in severely cognitively compromised patients). 
Results: Of 78 dyads randomized, 76 (50 HPA, 26 UC) were analyzed. Symptom burden 
(POS-S-MS) significantly reduced in HPA group compared to UC (p=0.047). Effect size 
was 0.20 at three, 0.32 at six months, and statistical significance borderline in per-
protocol analysis (p=0.062). Changes in SEIQoL-DW index did not differ in the two 
groups, as changes in secondary patient and carer outcomes. 
Conclusions: HPA slightly reduced symptoms burden. We found no evidence of HPA 
efficacy on patient quality of life, and on secondary outcomes. 
Trial registration number: ISRCTN73082124. 
Page 4 of 46
http://mc.manuscriptcentral.com/multiple-sclerosis
Multiple Sclerosis Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
INTRODUCTION 
Around 15% of multiple sclerosis (MS) patients have a progressive course from the 
outset, and a further 35% develop progressive disease after a variable period with 
relapsing disease (secondary progressive MS) [1]. International, multi-stakeholder 
initiatives have recently increased the focus on progressive MS, with the mission to 
speed up the development of therapies for people with this challenging disease form, 
most of whom are severely disabled for many years [2,3].  
Alignment of treatment with the patient’s needs, values and preferences, a core 
element of shared decision-making and palliative care (PC), should be routine aspect of 
care of any health professional (HP) and in any care setting. The provision of PC 
services, irrespective of diagnosis and illness stage, has been advocated, together with 
the development of such services for patients with neurological diseases [4-6]. In this 
context the integration of neurology, PC and rehabilitation competencies is key, as well 
as the individualized care provided by each discipline along the disease trajectory [7,8]. 
A consensus review concluded that there is limited evidence for the provision of PC for 
patients with progressive neurological diseases, and that further research into this 
area of care is urgently needed [9]. Two randomized controlled trials (RCTs) have been 
published on this regard: a UK trial on 52 MS patient-caregiver dyads comparing a 
three-month specialist PC service to standard care found no effect on the primary 
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outcome (emotional, psychological, and spiritual needs of MS patients). Nevertheless, 
some symptoms improved and informal caregiver burden was reduced compared to 
standard care [5]. The other (NE-PAL) RCT compared a four-month home specialist PC 
service to standard care in 50 people with advanced neurodegenerative disorders, 36% 
of whom had MS. The intervention significantly improved patient quality of life and 
some symptoms compared to standard care; but there was no effect on caregiver 
burden [10].  
We performed a multicenter RCT involving adults with severe MS and their carers to 
assess the effectiveness of a home-based palliative approach (HPA) added to usual 
care (UC). As for the RCTs reported above, we applied the framework for 
development/efficacy testing of complex interventions [11]. The results of the RCT are 
presented, except for the economic analysis and the nested qualitative study which 
will be presented in separate papers.  
 
METHODS 
Study design and participants 
In this randomized, examiner-blind, controlled study, we recruited patients from three 
Italian centers. The protocol was approved by the local ethics committees and the 
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study was undertaken in accordance with the Declaration of Helsinki [12]. The trial was 
registered at www.controlled-trials.com (ISRCTN73082124).  
Participants were non-institutionalized adults (age ≥ 18 years) with severe MS and 
their primary carers. Other patient inclusion criteria were primary or secondary 
progressive MS [1,13], Expanded Disability Status Scale (EDSS) score ≥ 8.0 [14], 
complex symptoms [15], and ≥ 2 unmet care needs [16]. The carer (a family member, 
relative, or friend of the patient) was his/her next of kin, and was designated by the 
patient except for patients with severe cognitive compromise. All patient-carer dyads 
gave written informed consent before study enrolment. 
 
Randomization and masking 
Dyads were randomly assigned (2:1) to receive HPA or UC. Allocation to treatment 
groups was done using a third-party, web-based computerised randomisation 
procedure with stratified minimization for: EDSS score (8.0-8.5, 9.0-9.5), presence of 
severe cognitive compromise (clinical judgement), and center.  
The trial senior statistician (RR) was not involved in study conduct. The blind examiners 
used a web-based case report form (eCRF), so that visit 1-3 data were available to HPA 
teams and coordination unit. After visits 2 and 3, examiners were asked to guess dyad 
assignment.  
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Intervention 
Based on the principles of PC [17], each center had a HPA team consisting of a 
physician (neurologist or physiatrist), a nurse (case manager and team leader), a 
psychologist, and a social worker. Nurses of the Milan and Rome centers had degrees 
and worked full time in PC; the Catania nurse attended a week-long individual training 
course. Prior to study start, all team members were trained in the HPA intervention; 
three and six months after trial initiation they met again to share experiences, fine-
tune the protocol, and discuss difficult cases. 
After a comprehensive assessment of the dyad needs based on direct observation and 
on visit 1 information (available via the eCRF), the HPA team defined the contents of 
the intervention, involving the dyad and the patient caring physician (the intervention 
was not intended to replace existing services). Subsequently, the team verified 
program implementation, and reviewed it as necessary. The team was not on call for 
dyads: in the event of emergencies, dyads contacted the patient caring physician or 
emergency medical services. All team activities were recorded in the PeNSAMI patient 
study record, which was kept at the patient’s home and available to all HPs/caregivers.  
 
UC consisted of the health and social services provided by the Italian National Health 
Service in the study area. Dyads assigned to UC received the three examiner visits 
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(visits 1-3) and the monthly telephone interviews, but not the HPA team visits (except 
visit 0). At the end of the study, dyads who received UC were offered the HPA. 
 
Outcomes 
The pre-specified primary endpoints were changes in patient quality of life (SEIQoL-
DW) and symptom burden (PC Outcome Scale-Symptoms-MS, POS-S-MS). The SEIQoL-
DW is administered in an interview in which respondents nominate the five areas of 
life that are most important in determining their QOL, and rate the 
satisfaction/functioning and weight/importance in each of these areas [18]. The 
SEIQoL-DW index can range from 0 to 100 (best). 
The POS-S-MS (primary outcome measure) and the core POS were developed and 
validated for use in PC [18,19]. POS consists of 10 items addressing emotional, 
psychological and spiritual needs, and provision of information and support, each 
scored from 0 to 4; POS total score can range from 0 to 40 (worst). POS-S-MS 
comprises 20 items relating to MS symptom burden (0 to 4 scale) plus an open 
question. Following advice of the POS-S-MS authors, we used the 17 pre-set items 
(POS-S-MS total score possible range 0 to 68 [worst]) [20]. For both core POS (version 
1) and POS-S-MS [http://pos-pal.org/maix/] we used the preceding seven days’ time 
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frame, and caregiver version of the scales in patients with severe cognitive 
impairment. 
In addition to core POS, patient secondary outcome measures were: the European 
Quality of life Five Dimensions (EQ-5D-3L) [21], the Hospital Anxiety and Depression 
Scale (HADS) [22], the Functional Independence Measure (FIM) [23], and direct and 
indirect tangible costs (assessed by the MS foundation Costs Questionnaire, MSCQ) 
[24]. Carer outcomes were: the Short Form 36 (SF-36) [25], the EQ-5D-3L, the HADS, 
and the Zarit Burden Interview (ZBI) [26].  
 
Statistical analysis 
The sample size was based on previous data for POS-S-MS [5] and SEIQoL-DW [10]. We 
expected that up to 50% of MS patients would have not be able to complete the 
SEIQoL-DW (severe cognitive compromise); in these the only primary endpoint was the 
POS-S-MS (caregiver version). 
For the POS-S-MS, we calculated that a sample size of 62 patients would yield a power 
of 85% to detect a mean score change of −0.4 (SD 0.5) in the HPA group compared to a 
change of 0.2 (SD 0.8; null hypothesis) in the UC group, at an α level of 0.05 [5]. 
Assuming 20% dropout, 49 patients were required in the HPA group and 25 patients in 
the UC group (total sample size 74). 
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For the SEIQoL-DW, we calculated that a sample size of 32 patients would yield a 
power of 80% to detect a mean score change of 12.1 (SD 12.8) in the HPA group 
compared to a change of -7.4 (SD 19.3) in the UC group, at an α level of 0.05 [10]. 
Assuming 20% dropout, 25 patients were required in the HPA group and 13 in the UC 
group (total sample size 38). 
All randomly assigned patients were included in the main intention-to-treat analysis, 
provided that at least one contact with the team occurred (HPA group). We compared 
the outcome score changes in the intervention groups by use of general linear model 
adjusting for baseline score. Missing data were imputed according to Rubin’s multiple 
imputation approach. A per-protocol analysis was also done for the primary outcomes 
and all secondary outcomes, and included patients who accomplished the outcome 
measures. For analysis of patient outcomes POS-S-MS, POS, and FIM, we used the 
following covariates: center, presence of severe cognitive impairment, and age 
(baseline EDSS score was not included in the model as it was associated with cognitive 
impairment). For analysis of patient outcomes SEIQoL-DW and HADS, we used the 
covariates center, baseline EDSS score, and age. We also tested for the first-order 
interaction term center per intervention group. For analysis of the ZBI total score, we 
used the covariates and interaction term reported above (first set of patient 
outcomes), plus carer’s age and gender, and carer living with the patient. Two-sided p 
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values of less than 0.05 were judged to be significant; p values were not adjusted for 
multiple comparisons. Analyses were done with Stata (version 13.0) and SAS (version 
9.4).  
 
RESULTS 
Dyad enrolment and characteristics  
Between January-November 2015, 50 dyads assigned to receive HPA and 26 assigned 
to receive UC were analysed (figure 1). Table 1 illustrates participant demographic and 
clinical characteristics at baseline.  
 
[Insert table 1 about here] 
 
HPA team activities  
Overall there were 360 home visits, 269 (75%) by one HP, 85 (24%) by two, and six 
(2%) by three or four HPs. On average dyads received 4.9 home visits in the first three 
months, and 2.8 in the second three months. The nurse (team leader) performed 152 
visits (33%), followed by the psychologist (25%), the physician (25%), and the social 
worker (17%). Figures were well balanced across centers (table 2) except for the 
number of visits performed by two or more HPs (Milan 4%, Rome 14%, Catania 51%; 
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p<0.001). Time from randomization to HPA team assessment was shorter in Catania 
(median 8 days) compared to Milan (11 days) and Rome (12.5 days; p=0.11).  
[Insert table 2 about here] 
 
Figure 2 reports the pre-specified care needs [16] addressed by the HPA teams, and 
those fulfilled at the end of the intervention, based on team reports. The most 
addressed care needs belonged to the domain ‘managing everyday life’ (38%), 
followed by ‘organization’ (34%) and ‘psychosocial’ (27%). A partial or complete 
fulfilment was reported for most ‘managing everyday life’ needs (97%), but for 
‘organization’ (73%) and ‘psychosocial’ (72%) dimensions fulfilment was lower, 
particularly for ‘access to services’ and ‘emotional wellbeing’ categories. These 
patterns appeared quite similar across the centers (online supplementary figure). In no 
instance spiritual needs were identified (or addressed). Discussion about advance care 
directives and end of life decisions was reported for two patients. 
 
Primary outcomes  
Mean change in POS-S-MS score from baseline to three months was 1.1 (95% CI -0.5 to 
2.7) in the HPA group and -0.2 (95% CI -2.9 to 2.6) in the UC group, with a mean 
between-group difference of -1.3 (95% CI -1.7 to 4.2), and a Cohen’s d effect size (ES) 
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of 0.20. Mean change in POS-S-MS from baseline to six months was 2.3 (95% CI 0.4 to 
4.1) in the HPA group and 0.3 (-2.0 to 2.6) in the UC group, with a mean between-
group difference of -1.9 (95% CI -1.1 to 5.0), and an ES of 0.32 (figure 3). The pre-
specified multivariate analysis is reported in table 3: HPA significantly reduced 
symptom burden (p=0.047), and there was no interaction between intervention and 
center (p=0.62). In the per-protocol analysis (supplementary table 1) the HPA effect on 
POS-S-MS was of borderline statistical significance (p=0.062).  
 
[Insert table 3 about here] 
 
The SEIQoL-DW interview was administered to 62 patients (82%; 41 HPA, 21 UC) 
without severe cognitive impairment. Mean change in SEIQoL-DW index score from 
baseline to three months was -0.9 (95% CI -6.8 to 5.1) in the HPA group and -3.7 (-17.6 
to 10.3) in the UC group, with a mean between group difference of 2.8 (95% CI -12.2 to 
17.8; ES 0.11). Mean change in SEIQoL-DW from baseline to six months was -0.8 (95% 
CI -5.3 to 6.9) in the HPA group and 4.0 (-21.1 to 13.1) in the UC group, with a mean 
between-group difference of 4.8 (95% CI -13.2 to 22.7; ES 0.10; figure 3). In the pre-
specified multivariate analysis, HPA had no significant effect on the primary outcome 
(p=0.57), and there was no interaction between intervention and center (p=0.70; table 
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3). Findings from the per-protocol analysis matched those of the main analysis (online 
supplementary table 1).  
 
Serious adverse events and attrition 
There were 22 serious adverse events (table 4) in 20 patients, 15 events in 13 patients 
on HPA (30%) and seven events in seven patients on UC (27%; p=0.78). Three HPA 
patients died, all deaths were deemed to be unrelated to the intervention. Three 
dyads discontinued the intervention, one in the HPA group and two in the UC group 
(figure 1); one HPA dyad completed the intervention but did not perform visit 3.  
 
[Insert table 4 about here] 
 
Other patient outcomes  
We found no significant difference between intervention groups for change at three 
and six months in POS, HADS Anxiety and Depression, and FIM total score (table 3). 
Two patients with baseline EDSS 8.0 worsened to EDSS 8.5 at three and six months 
visits (one from each intervention group), the other remained unchanged (data not 
shown). Per protocol analysis of secondary patient outcomes are reported in the 
online supplementary table 1. 
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Caregiver burden and other carer outcomes  
Mean change in ZBI score from baseline to three months was 1.1 ( 95% CI -1.7 to 3.9) 
in the HPA group and -0.5 (-4.1 to 3.2) in the UC group, with a mean between group 
difference of 1.6 (95% CI -3.1 to 6.2, ES 0.16). Mean change from baseline to six 
months was 0.2 (95% CI -2.8 to 3.2) in the HPA group and 1.7 (-1.1 to 4.5) in the UC 
group, with a mean between-group difference of -1.5 (95% CI -6.1 to 3.1, ES 0.16). 
There was no effect of HPA on ZBI score (p=0.83), or interaction between intervention 
and center (p=0.20; table 3). Per-protocol analysis findings matched those of the main 
analysis (online supplementary table 2).  
 
Examiner’s masking 
At visit 2, examiners guessed dyad assignment correctly in 12/73 (17%), incorrectly in 6 
(8%), and answered ‘don’t know’ in 55 (75%). Figures at visit 3 were 14% for correct, 
7% for incorrect, and 79% for ‘don’t know’ answers. Examiners guessed the correct 
assignment in both visits in four HPA dyads (9%) and one UC dyad (4%).  
 
DISCUSSION 
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In this six-month RCT in severely affected MS adults, a home-based palliative approach 
reduced symptom burden as assessed using the multidimensional POS-S-MS (primary 
outcome measure). The size of HPA effect was small, manifested at the end of the 
study, and the statistical significance was borderline. Three patients died during the 
study, all belonging to HPA group. The independent data and safety monitoring 
committee confirmed the center principal investigator judgment that these deaths 
were unrelated to the intervention. One further patient died immediately after 
baseline visit and the day before randomization, and one in the trial screening phase 
(figure 1). 
Reduction of symptom burden was in line with evidence from the UK trial, which found 
improvement in a subset of five POS-S-MS symptoms (pain, nausea, vomiting, mouth 
problems and sleeping difficulty) [5]. We identified no evidence of efficacy of the 
intervention for the SEIQoL-DW (primary outcome measure), or for secondary patient 
(POS, HADS, FIM), and carer outcomes (22-item ZBI, SF-36, HADS). Findings for 
caregiver burden were at odds with the UK trial, which found a significant 
improvement in those carers (13/26 in the PC group and 17/26 in the standard care 
group) who completed the 12-item ZBI [5]. It should be noted that findings on 
caregiver burden in PC interventions are conflicting, as highlighted by a recent 
systematic review and meta-analysis [27].  
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At main difference with the UK and Ne-Pal trials was that in PeNSAMI the teams 
involved did not originate from PC services, and this was not a specialist PC 
intervention [28]. The three HPA multi-professional teams were led by a nurse who 
received higher specialist training and worked full-time in PC (Milan and Rome) or had 
received PC training for the trial and worked full-time in MS rehabilitation (Catania); 
the physicians (one neurologist and two neurologists and physiatrists) and the other 
professionals were MS experts. The clinical characteristics of our patients were similar 
to those of the UK trial, but Ne-Pal included patients with other neurological 
conditions, and excluded patients with severe cognitive compromise [10]. As in the UK 
trial, the HPA teams addressed the identified needs of the dyads indirectly, by 
activating existing services or bringing them to the attention of the dyads, which was a 
major study challenge due to the fragmentation of care and silos working style of 
services [15,29]. This may have impacted the response to the intervention, which we 
originally hypothesized at three months. It is thus possible that as for the reduction in 
symptom burden (POS-S-MS) which manifested at six month visit (figure 3) the time of 
HPA care was insufficient to produce an effect on most outcome measures. Data from 
team records also documented a difficulty in HPA goal achievement especially for 
psychosocial and organizational issues, while for symptom management and activities 
of daily living needs were at least partially met in the six-month time frame (figure 2). 
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These issues also emerged from the focus group of the HPA teams conducted at the 
end of the trial (online supplementary box), and should be carefully considered in the 
design of future PC trials for MS patients, which should at best match with both service 
activation and the MS disease trajectory.  
Other differences with the two published RCTs which inspired our study are the 
adoption of a multicenter design, and an examiner-blind design (the nature of the 
intervention prevented us from blinding patients and carers to their allocated group). 
The latter made more complex (and burdensome) the study procedures: the SEIQoL-
DW interview was not administered by the HPA team (team members could only 
access SEIQoL-DW data of the patient via the eCRF), and participants had sometimes 
difficulty in distinguishing HPA team and examiner roles. In addition, the examiner’s 
visits (particularly the SEIQoL-DW interview), and the monthly telephone interviews 
may have produced some non-specific effect in the UC group, which might have 
moderated the occurrence of performance bias [30]. However, an examiner-blind 
design improves the quality of the study by preventing ascertainment bias [30]. Inter-
rater reliability (in outcome ascertainment) was a minor issue as in Milan and Catania 
outcome measures were obtained by the center’s main examiner only, and in Rome 
both trained examiners (main and backup) operated. We met our recruitment and 
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retention targets, and missing data on both patient and carer outcomes were <10% – 
well below our pre-specified hypothesis [12], and data of RCTs on PC [27,31].  
It is essential to have QOL as a primary outcome measure for a PC intervention [17]. 
We chose the SEIQoL-DW interview as it is an individualized tool, preventing patient 
exposure to non-pertinent or frustrating items, and the oversight of significant QOL 
dimensions. Ne-Pal findings provided evidence of the feasibility of SEIQoL-DW 
administration in this disabled patient population, and good scale responsiveness [10]. 
However, in view of the PeNSAMI trial experience, this instrument may have a higher 
potential in the hands of the treating professionals (here the HPA team), as it can be 
used to elucidate patient values and priorities, and thus facilitate the setting of goals 
that are aligned to such values [32]. 
To conclude, PeNSAMI trial showed that six-month HPA slightly reduces MS symptom 
burden, but did not produce evidence of an effect on patient QOL, or on the 
multifaceted patient-carer needs. Moreover, our findings suggest that a PC 
intervention for patients with severe MS may need to be over a longer period than six 
months. The trial was designed and conducted to minimize the risk of bias, at the 
expense of some burden for patients, carers, and health professionals. The analysis of 
the qualitative study nested in the RCT, by addressing the living experiences of 
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participants, will supplement trial findings, identify the strengths and challenges of the 
intervention, and contribute to improve intervention’s contents, processes and timing.  
 
APPENDIX 
PeNSAMI project Investigators 
Steering Committee: R Amadeo: Italian Multiple Sclerosis Society (AISM); A Giordano, 
M Ponzio, MG Grasso, A Lugaresi, F Patti, G Martino: Italian Multiple Sclerosis Society 
(AISM), Genoa; L Palmisano: Istituto Superiore di Sanità, Rome; S Veronese, P Zaratin, 
MA Battaglia, A Solari. 
Data Management and Analysis Committee: A Giordano; E Pagano (cost analysis): 
Unit of Cancer Epidemiology, "Città della Salute e della Scienza" University Hospital of 
Turin and CPO Piemonte, Turin; D Radice (statistician): Division of Epidemiology and 
Biostatistics, European Institute of Oncology, Milan; M Farinotti, G Ferrari; A Solari, R 
Rosato (statistician): Department of Psychology, University of Turin. 
Independent Data and Safety Monitoring Committee: DJ Oliver (Chair): University of 
Kent, Rochester, Kent, UK; E Pucci: Neurology Unit, Ospedale Provinciale di Macerata, 
Macerata; L Tesio: Department of Biomedical Sciences for Health, University of Milan, 
Milan; The Istituto Auxologico Italiano, IRCCS, Milan. 
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Qualitative Analysis Panel: E Bianchi, S Cilia: University Hospital Policlinico Vittorio 
Emanuele, Catania; S Cipollari: IRCCS S Lucia Foundation, Rome; E Pietrolongo, M 
Giuntoli, C Borreani. 
Literature Review Panel: MG Grasso, L Palmisano, A Fittipaldo, A Giordano. 
Intervention Panel: C Cugno, R Causarano, P Morino: ‘Ex Convento delle Oblate’ 
Hospice, Local Health Unit of Florence, Florence; S Veronese. 
Enrolling Centers and Investigators: Foundation IRCCS Neurological Institute C Besta, 
Milan: P Confalonieri, E Rossetti, AM Giovannetti, V Torri Clerici, A Totis, A Campanella, 
M Farinotti, A Fittipaldo, G Ferrari, R Mantegazza, A Giordano, A Solari; IRCCS S Lucia 
Foundation, Rome: MG Grasso, MC Stefanelli, I Rossi, L Tucci, F Ippoliti, G Morone, A 
Fusco; University Hospital Policlinico Vittorio Emanuele, Catania: F Patti, C Cavallaro, A 
Pappalardo, V Cascio, G Occhipinti, V Cimino, F Zagari. 
Other Centers and Investigators: AISM Liguria Region Rehabilitation Service, Genoa: 
ML Lopes de Carvalho, M Giuntoli, R Motta, MA Battaglia; G d’Annunzio University, 
Chieti-Pescara, Chieti: A Lugaresi, E Pietrolongo, M Onofrj; FARO Charitable 
Foundation, Turin: S Veronese, C Cugno; Niguarda Ca’ Granda Hospital, Milan: R 
Causarano, D Da Col; Antea Charitable Association, Rome: G Casale, MC Stefanelli; 
Foundation IRCCS Istituto Nazionale per la Cura dei Tumori, Milan: C Borreani, E 
Bianchi. 
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Table 1. Baseline characteristics of the 76 MS patient-carer dyads at baseline, by allocated group. There 
were no significant differences between the groups except for carer education (p=0.04), and for SF-36 
Mental Composite (p=0.02). 
Characteristic Home palliative approach 
(N = 50) 
Usual care 
(N = 26) 
MS patients N (%) 
Women  31 (62) 12 (46) 
Age (years)
1
 60.5 ± 9.7 56.8 ± 9.5 
Education: No education completed   1 (  2)   0 
Primary (5–8 years) 19 (38) 10 (38) 
Secondary (12–13 years) 20 (40) 10 (38) 
                     College/University (14+ years) 10 (20)   6 (24) 
Occupation: Employed    2 (  4)   2 (  7) 
Retired (age)    9 (18)   1 (  4) 
Unemployed     0   1 (  4) 
Retired (disability) 39 (78) 22 (85) 
Age at MS diagnosis (years)
1
 37.5 ± 13.8 35.7 ± 10.9 
Severe cognitive compromise   9 (18)   5 (19) 
SEIQoL-DW
1,3
  61.3 ± 21.5 59.5 ± 30.0 
POS-S-MS
1
 23.7 ± 8.8 23.9 ± 8.4 
POS
1
 12.1 ± 6.8 12.0 ± 7.2 
EDSS
2
   8.5 (8.0–9.5)   8.5 (8.0–9.5) 
FIM total
1.
 49.3 ± 16.9 52.6 ± 22.0 
HADS Anxiety
1,3
    6.4 ± 3.9    6.6 ± 3.9 
Depression
1,3
    6.9 ± 4.4   7.1 ± 3.6 
Carers  
Women  31 (62) 16 (61) 
Age (years)
1
 60.1 ± 13.9 60.8 ± 11.1 
Education: Primary (5–8 years) 18 (36)   7 (27) 
Secondary (12–13 years) 16 (32) 16 (62) 
                    College/University (14+ years) 16 (32)   3 (11) 
Occupation: Employed/student  23 (46)  13 (50) 
Retired (age)  19 (38)   6 (23) 
Housewife    6 (12)   7 (27) 
Unemployed     2 (  4)   0 
Relation:   Spouse/partner 25 (50) 15 (58) 
Parent    8 (16)   4 (15) 
Other relative   7 (14)   6 (23) 
Son/daughter   8 (16)   0 
Paid caregiver    2 (  4)   1 (  4) 
ZBI total score
1
 35.9 ± 15.3 34.1 ± 12.5 
SF-36 Physical Composite
1,4
 44.4 ± 10.9 43.2 ± 11.8 
Mental Composite
1,4
 38.4 ± 9.1 43.6 ± 10.9 
HADS Anxiety
1
    9.3 ± 4.0   8.0 ± 4.4 
Depression
1
    7.1 ± 4.1    7.0 ± 5.2 
EDSS, Expanded Disability Status Scale; FIM, Functional Independence Measure; HADS, Hospital 
Anxiety and Depression Scale; MS, Multiple sclerosis; POS, Palliative care Outcome Scale; POS-S-
MS, Palliative care Outcome Scale-Symptoms-Multiple Sclerosis; SEIQoL-DW, Schedule for the 
Evaluation of Individual Quality of Life-Direct Weighting; SF-36, Short Form 36; ZBI, Zarit Burden 
Interview. 
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1. Mean ± standard deviation.  
2. Median (range). 
3. Assessed in 41 (82%) home palliative approach and 21 (81%) usual care patients who had no severe 
cognitive impairment.  
4. For five home palliative approach and two usual care carers, Physical and Mental Composites were 
not calculated, in all cases due to missing items. 
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Table 2. Home palliative approach (HPA) team activities in the three participating centers. All activities (except for HPA team meetings) were performed at 
patient’s home. 
Characteristic Milan  Rome  Catania 
  N (%)  
Dyads assessed 16  15 19 
Dyads who completed the first three months 16 (100%) 13 (87%) 18 (95%) 
Dyads who completed the second three months 16 (100%) 12 (80%) 17 (89%) 
Time from randomization to HPA team assessment (days)
1
 11.4, 11.0 (4–29) 13.5, 12.5 (3–28)   9.3, 8.0 (2–25) 
Dyads assessed >14 days from randomization    3 (20%)   5 (36%)   3 (16%) 
HPA team visits, months 1-3 79 (4.9 per dyad) 64 (4.9 per dyad) 89 (4.9 per dyad) 
HPA team visits, months 4-6 46 (2.9 per dyad) 28 (2.3 per dyad) 54 (3.2 per dyad) 
Number of professionals involved in the home visits: 1 120 (96%) 79 (86%) 70 (49%) 
    2   5 (  4%) 13 (14%) 67 (47%) 
    3, 4   0 (  0%)    0 (  0%)   6  (  4%) 
Type of health professional: Nurse (team leader) 38 (29%) 36 (34%) 78 (34%) 
Psychologist 38 (29%) 26 (25%) 54 (24%) 
Physician 24 (18%) 25 (24%) 66 (29%) 
                                                   Social worker 30 (23%) 18 (17%) 29 (13%) 
1. Mean, median (range) 
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Table 3. Generalized linear models (intention to treat analysis) of patient outcomes and of the Zarit Burden 
Interview (ZBI). EDSS is Expanded Disability Status Scale, HPA is home palliative approach, UC is usual care. 
All estimates are adjusted for time visit and for the basal value of the dependent variable. Treatment effect 
by center is reported when the interaction term is statistically significant.  
Palliative care Outcome Scale-Symptoms-Multiple Sclerosis (POS-S-MS) score – primary outcome 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -2.10 (-4.18 – -0.03)  0.047 
Rome (vs. Milan)   1.04 (-1.45 –  3.52) 0.41 
Catania (vs. Milan)   0.82 (-1.58 –  3.21) 0.50 
Age (years)   0.12 (  0.01 – 0.22) 0.026 
Severe cognitive compromise    3.54 (  0.83 – 6.26) 0.010 
Intervention group x center                    – 0.62 
  
Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) index – primary 
outcome 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -2.49 (-11.15 –  6.17)  0.57 
Rome (vs. Milan) -3.82 (-15.09 –  7.45) 0.51 
Catania (vs. Milan)   4.58 ( -5.97 – 15.13) 0.39 
Age (years) -0.11 ( -0.55 –    0.33) 0.62 
EDSS score at baseline -7.11 (-19.00 –   4.78) 0.24 
Intervention group x center                  – 0.70 
 
Palliative care Outcome Scale (POS) score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -1.18 (-3.11 – 0.76)     0.23 
Rome (vs. Milan)   1.29 (-1.12 – 3.70)    0.29 
Catania (vs. Milan)   4.74 ( 2.43 – 7.03) < 0.001 
Age (years)   0.08 (-0.02 – 0.19)    0.12 
Severe cognitive compromise    3.86 ( 1.41 – 6.32)    0.002 
Intervention group x center
 
                 –    0.70 
 
 
Hospital Anxiety and Depression Scale (HADS) Anxiety score  
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  0.52 (-0.93 – 1.98)    0.48 
Rome (vs. Milan)  1.23 (-0.62 – 3.08)    0.19 
Catania (vs. Milan)  3.46 ( 1.69 – 5.24) < 0.001 
Age (years)  0.03 (-0.04 – 0.10)    0.46 
EDSS score at baseline -0.41 (-2.41 – 1.59)    0.69 
Intervention group x center                    –    0.24 
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Hospital Anxiety and Depression Scale (HADS) Depression score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)   0.72 (-0.55 – 1.99)     0.26 
Rome (vs. Milan) -0.29 (-2.04 – 1.45)     0.74 
Catania (vs. Milan)   2.48 ( 0.95 – 4.01)     0.001 
Age (years)   0.08 ( 0.01 – 0.15)    0.02 
EDSS score at baseline    2.34 (-0.51 – 4.19)    0.01 
Intervention group x center                 –    0.02 
   
HPA (vs. UC) in Milan    2.13 (-0.01 – 4.27)      0.05 
                       in Rome    1.97 (-0.17 – 4.12)     0.07 
                       in Catania   -1.39 (-3.31 – 0.52)      0.15 
 
Functional Independence Measure (FIM) total score 
 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -0.05 (-0.75 – 0.64)     0.88 
Rome (vs. Milan)   0.26 (-0.64 – 1.15)    0.57 
Catania (vs. Milan)   0.15 (-0.65 – 0.94)    0.71 
Age (years)  -0.03 (-0.07 – 0.00)    0.06 
Severe cognitive compromise    0.23 (-0.87 – 1.34)    0.68 
Intervention group x center                  –    0.56 
 
Zarit Burden Interview (ZBI) score  
 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -0.41 (-4.30 – 3.48)       0.83 
Rome (vs. Milan)   0.76 (-3.74 – 5.25)   0.74 
Catania (vs. Milan) -1.27 (-5.86 – 3.31)   0.58 
Patient age (years)   0.09 (-0.11 – 0.30)   0.38 
Patient with severe cognitive compromise  -2.10 (-6.92 – 2.72)   0.39 
Carer age (years)   0.00 (-0.14 – 0.15)   0.95 
Female carer -2.93 (-7.41 – 1.53)   0.19 
Living with the patient   0.38 (-5.84 – 6.61)   0.90 
Intervention group x center                –   0.20 
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Table 4. The 22 serious adverse events (20 patients) listed by report date (day/month/year). All were emergency ward admissions except the event of patient 
code 0318 (home death).  
Patient 
code 
Group Baseline 
EDSS  
Randomization 
date  
Report  
date  
Event 
Date 
Weeks from  
randomization 
Event description  Outcome  
0315 HPA  9.0  08/04/15 11/05/15 05/05/15   4 Ab-ingestis pneumonia  Resolved (discharged)  
0311 UC  8.5  07/03/15 18/05/15 06/04/15   4 Generalized anxiety  Resolved (discharged)  
0211 HPA  8.0  13/05/15 26/05/15 23/05/15   1 Cardiac failure  Death (13 days H) 
0314 HPA 8.5  22/03/15 27/05/15 11/05/15   7 Acute respiratory failure  Death (emergency ward)  
0112 UC  9.5  23/03/15 28/05/15 12/05/15   7 Breathing difficulty  Resolved (21 days H) 
0203 UC  8.5  03/03/15 03/06/15 27/05/15 12 Urine retention  Resolved (6 days H) 
0111 HPA 9.0  17/03/15 16/06/15 08/05/15   7 Anarthria  Resolved (3 days H) 
0305 UC  8.5  24/02/15 29/06/15 11/06/15 15 Contact dermatitis  Resolved (7 days H) 
0321 UC  9.5  30/05/15 20/07/15 10/07/15   5 Dysphagia  Gastrostomy tube 
placement (3 days H) 
0308 HPA 8.0  14/03/25 12/08/15 07/08/15 21 Breathing difficulty, vomiting  Resolved (1 day H) 
0318 HPA 8.5  02/05/15 12/08/15 07/08/15 14 Cardiac failure  Death (home)  
0203 UC  8.5  03/03/15 04/09/15 30/08/15 26 Bladder catheter malfunctioning  Resolved (discharged) 
0213 HPA 9.0  04/06/15 14/10/15 29/09/15 16 Fever, breathing difficulty  Resolved (discharged) 
0322 HPA 9.0  30/05/15 09/10/15 02/09/15 13 Acute urine retention/infection  Resolved (discharged) 
0218 HPA 8.5 30/07/15 07/01/16 26/12/15 21 Arrhythmia Resolved (3 days H) 
0328 HPA 8.5 25/07/15 16/01/16 22/12/15 22 Necrotizing fasciitis   Day surgery (discharged) 
0136 UC 8.0 28/10/15 20/01/16 11/12/15   6 Traumatic wound  Resolved (wound suture) 
0220 HPA 9.0 02/10/15 13/02/16 23/01/16 16 Fever, macrohematuria  Resolved (1 day H) 
0137 HPA 8.0 06/11/15 04/03/16 23/02/16 15 Difficulty with bladder catheter removal Resolved (discharged) 
0138 HPA 8.5 18/11/15 21/03/16 19/02/16 13 Acute urine retention, constipation Resolved (discharged) 
     22/02/16 13 Acute urine retention, abdominalgya Resolved (discharged) 
     01/03/16 15 Fever, bronchitis, macrohematuria  Resolved (1 day H) 
EDSS, Expanded Disability Status Scale; H, hospitalization; HPA, home palliative approach; UC, usual care. 
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Figure legends 
Figure 1. CONSORT 2010 Flow diagram of the trial. HPA is home palliative approach, UC is usual care. 
Figure 2. The care needs addressed (dark grey, overall n=338) and fulfilled (light grey, n=276) as reported 
by the home palliative approach (HPA) teams. Care needs are grouped into 11 pre-set categories and three 
domains [16]. 
Figure 3. Change in the two primary outcome measures Palliative care Outcome Measure-Symptoms-
Multiple Sclerosis (POS-S-MS) and Schedule for the Evaluation of Individual Quality of Life-Direct Weighting 
(SEIQoL-DW) by intervention group (intention to treat data). CI is confidence interval, HPA is home 
palliative approach, UC is usual care. 
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Figure 1. CONSORT 2010 Flow diagram of the trial. HPA is home palliative approach, UC is usual care.  
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Figure 2. The care needs addressed (dark grey, overall n=338) and fulfilled (light grey, n=276) as reported 
by the home palliative approach (HPA) teams. Care needs are grouped into 11 pre-set categories and three 
domains [16].  
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Figure 3. Change in the two primary outcome measures Palliative care Outcome Measure-Symptoms-
Multiple Sclerosis (POS-S-MS) and Schedule for the Evaluation of Individual Quality of Life-Direct Weighting 
(SEIQoL-DW) by intervention group (intention to treat data). CI is confidence interval, HPA is home 
palliative approach, UC is usual care.  
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Supplementary figure. The care needs addressed (dark grey, Milan n=119; Rome n=101; Catania n=119) 
and fulfilled (light grey, Milan n=101; Rome n=83; Catania n=92) as reported by the home palliative 
approach (HPA) teams. Care needs are grouped into 11 pre-set categories and three domains [16]. 
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              Catania 
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Solari et al., 2017 
Supplementary table 1. Generalized linear models (per protocol analysis) of patient outcomes. EDSS is 
Expanded Disability Status Scale, HPA is home palliative approach, UC is usual care. All estimates are 
adjusted for time visit and for the basal value of the dependent variable. Treatment effect by center is 
reported when the interaction term is statistically significant.  
 
Palliative care Outcome scale-Symptoms-Multiple Sclerosis (POS-S-MS)  score – primary outcome 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -1.94 (-3.98 –  0.09)  0.062 
Rome (vs. Milan)   1.40 (-1.09 –  3.89) 0.27 
Catania (vs. Milan)   0.86 (-1.47 –  3.20) 0.47 
Age (years)   0.13 (  0.02 – 0.24) 0.014 
Severe cognitive compromise    3.56 (  0.92 – 6.20) 0.008 
Intervention group x center                  – 0.74 
 
Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) index  – 
primary outcome 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -2.26 (-10.98 –  6.44)  0.61 
Rome (vs. Milan) -5.56 (-17.49 –  6.37) 0.36 
Catania (vs. Milan)  3.19 ( -7.57 – 13.95) 0.56 
Age (years) -0.17 ( -0.65 –    0.29) 0.46 
EDSS score at baseline -5.81 (-18.28 –   6.66) 0.36 
Intervention group x center                     – 0.71 
 
Palliative care Outcome Sale (POS) score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -1.23 (-3.16 – 0.69)  0.21 
Rome (vs. Milan)  1.06 (-1.27 – 3.41)  0.37 
Catania (vs. Milan)  4.65 ( 2.38 – 6.92)  < 0.001 
Age (years)  0.08 (-0.02 – 0..17)  0.11 
Severe cognitive compromise   3.87 ( 1.47 – 6.28) 0.002 
Intervention group x center
 
                 – 0.62 
 
Hospital Anxiety and Depression (HADS) Anxiety score  
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  0.56 (-0.93 –  2.06)    0.46 
Rome (vs. Milan)  1.39 (-0.61 –  3.39)   0.17 
Catania (vs. Milan)  3.54 ( 1.67 –  5.41) <0.001 
Age (years)  0.03 (-0.04 –  0.11)   0.40 
EDSS at baseline -0.55 (-2.68 –  1.56)   0.60 
Intervention group x center                  –   0.27 
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Hospital Anxiety and Depression (HADS) Depression score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)   0.68 (-0.60 –  1.96)    0.29 
Rome (vs. Milan) -0.56 (-2.28 –  1.16)   0.52 
Catania (vs. Milan)  2.42 (  0.84 –  4.01)   0.003 
Age (years)  0.08 (  0.01 –  0.15)   0.02 
EDSS score at baseline   2.58 (  0.32 –  0.63)   0.01 
Intervention group x center                   –   0.02 
   
HPA (vs. UC) in Milan   2.19 (  0.06 –  4.34)   0.04 
                       in Rome   1.83 ( -0.03 –  3.97)   0.09 
                       in Catania  -1.41 ( -3.33 –  0.50)   0.01 
 
 
Functional Independence Measure (FIM) total score 
 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  -0.10 (-0.84 –  0.63)    0.77 
Rome (vs. Milan)   0.26 (-0.65 – 1.18)   0.57 
Catania (vs. Milan)   0.01 (-0.81 – 0.85)   0.96 
Age (years)  -0.04 (-0.08 –  -0.00)    0.02 
Severe cognitive compromise    0.29 (-0.89 – 1.47)   0.63 
Intervention group x center                  –   0.57 
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Supplementary table 2. Generalized linear models (per protocol analysis) of carer’s Zarit Burden Interview 
(ZBI), Hospital Anxiety and Depression Scale (HADS), and SF-36 composite scores. HPA is home palliative 
approach, UC is usual care. All estimates are adjusted for time visit and for the basal value of the 
dependent variable. Treatment effect by center is reported when the interaction term is statistically 
significant.  
 
ZBI score  
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)   -0.44 (-4.29 – 3.40)   0.82 
Rome (vs. Milan)    0.84 (-3.88 – 5.57)   0.72 
Catania (vs. Milan)   -1.78 (-6.41 – 2.84)   0.45 
Patient age (years)    0.04 (-0.16 – 0.25)   0.66 
Patient with severe cognitive compromise    -2.40 (-7.17 – 2.37)   0.32 
Carer age (years)   -0.19 (-0.17 – 0.13)   0.80 
Female carer   -2.23 (-6.20 – 1.72)   0.26 
Living with the patient    0.92 (-5.13 – 6.97)    0.76 
Intervention group x center                  –   0.14 
 
HADS Anxiety score  
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  0.43 (-0.84 –  1.69)    0.50 
Rome (vs. Milan) -0.31 (-1.85 –  1.21)   0.68 
Catania (vs. Milan) -0.20 (-1.74 –  1.34)   0.79 
Patient age (years)  0.01 (-0.05 –  0.07)   0.75 
Patient with severe cognitive compromise  -0.88 (-2.47 –  0.70)   0.27 
Carer age (years)   0.03 (-0.01 –  0.08)   0.20 
Female carer   2.06 (  0.73 –  3.39)   0.002 
Living with the patient -0.65 (-2.60 –   1.29)   0.51 
Intervention group x center                 –   0.62 
 
HADS Depression score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  0.49 (-0.78 –  1.77)    0.45 
Rome (vs. Milan) -0.25 (-1.82 –  1.32)   0.75 
Catania (vs. Milan)  0.32 (-1.24 –  1.88)   0.68 
Patient age (years)  0.02 (-0.04 –  0.08)   0.53 
Patient with severe cognitive compromise  -0.03 (-1.65 –  1.58)   0.96 
Carer age (years)  0.07 ( 0.02 –  0.12)   0.003 
Female carer  1.34 ( 0.01 –  2.67)   0.047 
Living with the patient  0.25 (-1.79 –  2.30)   0.80 
Intervention group x center                  –   0.37 
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SF-36 Physical Composite score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC) -0.21 (-2.88 – 2.44)    0.87 
Rome (vs. Milan)  3.43 ( 0.11 –  6.75)   0.04 
Catania (vs. Milan)  1.95 (-1.27 – 5.17)   0.23 
Patient age (years) -0.01 (-0.12 – 0.15)   0.82 
Patient with severe cognitive compromise  -0.09 (-3.27 – 3.08)   0.95 
Carer age (years) -0.07 (-0.18 – 0.03)   0.16 
Female carer  0.51 (-2.24 – 3.26)   0.71 
Living with the patient  0.12 (-3.87 – 4.12)   0.95 
Intervention group x center                  –   0.26 
 
SF-36 Mental Composite score 
Covariate Coefficient (95% CI) P value 
HPA (vs. UC)  0.09 (-3.63 – 3.81)    0.96 
Rome (vs. Milan) -0.75 (-5.29 – 3.79)   0.74 
Catania (vs. Milan) -3.60 (-8.04 – 0.84)   0.11 
Patient age (years) -0.02 (-0.21 – 0.16)   0.82 
Patient with severe cognitive compromise  -2.85 (-7.21 – 1.51)   0.20 
Carer age (years) -0.06 (-0.19 – 0.07)   0.39 
Female carer  1.39 (-2.47 – 5.25)   0.48 
Living with the patient  0.04 (-5.51 – 5.59)   0.98 
Intervention group x center                  –   0.04 
   
HPA (vs. UC) in Milan  -6.73 (-13.30 – -0.16)   0.04 
                       in Rome   1.87 (  -4.55 –  8.31)   0.56 
                       in Catania   3.51 (  -2.18 –  9.21)   0.22 
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Supplementary box. Main challenges to intervention delivery identified (thematic analysis) in the HPA 
team focus group meeting conducted at the end of the trial. The five themes were: (1) the indirect role of 
the teams (according to the trial protocol); (2) the limited availability/responsiveness of the local services; 
(3) a general submission and difficulty of the dyads to express their needs; 4) team working issues, 
particularly those pertaining to newly-formed teams, acting at patient home; 5) emotional involvement.  
 
 
1. Indirect role of the teams  
“It’s an additional burden to them [the dyads] and also a reason of frustration because they still seek 
support, they seek help, but then in fact, apart from mediating the relationships with the local health 
providers, the offices and so on, we couldn’t do anything else. " [Psychologist, Rome team]  
 
“It was clear that our role was not of direct care, it was a facilitating role, therefore, to say the 
representation was clear, the problem was how to do that in practice, how to accomplish… " [Psychologist, 
Milan team]  
 
“l had a difficult time understanding what to do, what I could and it was really right to do according to the 
study objectives” [Neurologist, Milan team] 
 
2. Limited availability/responsiveness of the local services  
"One can be a facilitator when services are in place, but when no services are available what do I facilitate? 
In Rome, for example, so many of them do not make rehabilitation at the centers anymore, as they have 
difficulty getting around, ambulances cost so much, etc." [Psychologist, Roma team]  
 
"You have difficulty in contacting the GP, and when you finally make it, he says: "well, there you are, one 
more reason not to involve me"; that is to say, they’re good professionals, but obviously in this system they 
have a hard time, such a hard time…" [Nurse, Milan team]  
 
"[Neurologists] know nothing of what has happened, they have not heard from them, not viewed them, so 
it's tricky to involve them, inform them, make them participate to what you’re doing at home" [Psychologist, 
Roma team]  
 
"I have a little informed them, I sent them emails where I made a summary of the study practically, and then 
to each doctor we sent our relations, the social, the psychological, the nurse and medical relation. But no 
answer… " [Nurse, Catania team]  
 
3. Difficulty of the dyads to express their needs  
“In these countless years of illness [patients and informal carers] got accustomed to not having the services, 
to not receiving, to have bureaucratic problems, whenever they need to solve a problem they must still 
make some laps, then, they were not expecting great things from us" [Nurse, Rome team] 
 
"We received many expressed questions but a great deal of unspoken questions: they came out, that is, they 
asked for help on issues that apparently were organizational, but in fact were about conflicts between 
family members that had deteriorated, impacting on patient care and organization... These occurrences 
were crucial and taxing for us, as by recognizing these unexpressed questions, it was up to us figuring 
whether, how and when there were intervention areas, or not." [Social worker, Catania team] 
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"What impressed me most was the difficulty for the dyads to try to explore their needs, as if they were not 
used to doing this. I guess the first time they really approached this was when they performed the baseline 
visit ... For the relatives it was too difficult to express their personal needs, as all their needs were linked in 
some way to the needs of the patient… this required time and work." [Psychologist, Milan team] 
 
"… and for years [problems] are kept there, you have no access, they too have no access, so even if you 
become aware because of some dynamics that there are problems, they [the dyads] do not acknowledge 
this." [Psychologist, Rome team] 
 
"There were also unmet needs regarding the treatment of certain symptoms. Pain is one of the symptoms 
that most of them have, but they’ve got used to it, they talk about pain as something normal, so I imagine 
other important physical problems they live with for such a long time.” [Nurse, Rome team] 
 
4. Team working issues  
“To me, yielding ground to the other colleagues when meeting the expectations of the patient was hard, 
perhaps because most needs were about medical issues." [Neurologist, Catania team] 
 
“Working as a team, as a group, was a bit difficult, I’m not sure whether we as a group needed more 
training or whether this need was more general, and regarded how to manage those dynamics that usually 
manifest within a group.” [Social worker, Catania team] 
 
“Team members had specific competences, but some like me lacked skills on the care of MS patients, so I 
had to gain knowledge on a new disease... this was added to the need to become familiar with the other 
team members.” [Nurse, Rome team] 
 
5. Emotional involvement  
“In spite of the fact that we’re fairly seasoned professionals, the emotional load and involvement were 
remarkable. Getting into patient houses and finding relationship difficulties, psychological conflicts... an 
enormous emotional burden which willy-nilly we have in part taken charge of." [Social Worker, Catania 
team] 
 
"And then at the end there was a sense of frustration over what you actually can do… All in all, you can only 
say: the study ends, they are still there with their mess..." [Nurse, Milan team] 
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